Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars - Seite 2
As an innovation-led biopharmaceutical company, Biocon has successfully developed and taken a range of novel biologics, biosimilar antibodies, rh-insulin and insulin analogs from 'lab to market'. The collaboration with Sandoz builds upon Biocon's successful progress in its existing global biosimilars program. An early mover in the biosimilars space, Biocon has successfully launched its insulin glargine in Japan, trastuzumab and bevacizumab biosimilars in India and rh-insulin, insulin glargine and biosimilar trastuzumab in a few emerging markets; and it was the first Indian company to have a biosimilar approved by the US Food and Drug Administration.
Lesen Sie auch
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be
identified by words such as "to develop," "to commercialize," "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline,"
"launch," "expansion," "portfolio," "collaboration," "partnership," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for
the investigational or approved biosimilar products described in this press release, or regarding potential future revenues from such products or the collaboration and partnership with Biocon. You
should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known
and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those
set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for
any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such biosimilar products will be approved for all indications
included in the reference product's label. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the collaboration
and partnership with Biocon will achieve any or all of its intended goals and objectives, or be commercially successful. In particular, our expectations regarding such products, and the
collaboration and partnership with Biocon, could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis
of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including
potential approval of additional biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement
pressures; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz or Biocon from selling the products developed, manufactured and
commercialized under the collaboration and partnership; general economic and industry conditions, including the effects of the persistently weak economic and financial environment in many
countries; potential or actual data security and data privacy issues; safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file
with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information, future events or otherwise.